m6A regulator-mediated methylation modification patterns and tumor immune microenvironment characterization in endometrial cancer
Genes & Diseases · 2023-11 · 10 (6) · 2278-2281
DOI: 10.1016/j.gendis.2023.01.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes & Diseases, 2023-11. Verfasst von Kexin Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Institute of Biomedicine, C…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Project, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Endometrial cancer (EC) is the second most prevalent female reproductive system tumor after cervical cancer and its incidence is rising globally. Recently, N6-methyladenosine (mA) has emerged as an important regulator of a variety of physiological and pathological processes, especially in promoting EC progression. However, the potential roles of mA modification in EC and its immune landscape remain unknown. Here, the correlation between mA modification patterns and tumor microenvironment (TME) cell-infiltrating characteristics was comprehensively evaluated based on 21 mA regulators of 1301 endometrial cancer samples. We identified four m6Aclasses characterized by distinct TME cell infiltration. We used principal component analysis algorithms to construct m6Ascore to quantify mA modification patterns of endometrial cancer individuals. Our results showed that lower m6Ascore may be closely related to immune-inflamed phenotype and displayed immune-activated characteristics and better prognosis, while higher m6Ascore may be associated with immune-desert and immune-excluded phenotype and showed interstitial activation-related characteristics and poor prognosis. These new findings reveal that mA modification played a nonnegligible role in the formation of TME diversity and complexity and support the possibility of targeting mA modification patterns for rescuing EC, which were unreported in EC patients. To clarify this, we integrated the genomic information of EC samples to comprehensively evaluate the mA modification patterns. The baseline information of all eligible EC datasets was summarized in Table S1. Among the 530 samples, 176 experienced mA regulators mutations, with a frequency of 33.21% (Fig. S1A). Copy number variation
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, Gu…
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, China.
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, Guangzhou, Guangdong 51063…
Förderung
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Project
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Li, K., Shu, S., Zou, J., Li, M., & Liu, Z. (2023). m6A regulator-mediated methylation modification patterns and tumor immune microenvironment characterization in endometrial cancer. Genes & Diseases, 10(6), 2278-2281. https://doi.org/10.1016/j.gendis.2023.01.021
Vancouver
Li K, Shu S, Zou J, Li M, Liu Z. m6A regulator-mediated methylation modification patterns and tumor immune microenvironment characterization in endometrial cancer. Genes & Diseases. 2023;10(6):2278-2281. doi:10.1016/j.gendis.2023.01.021
BibTeX
@article{Li2023,
author = {Li, Kexin and Shu, Shanrong and Zou, Jiahua and Li, Manmei and Liu, Zhong},
title = {m6A regulator-mediated methylation modification patterns and tumor immune microenvironment characterization in endometrial cancer},
journal = {Genes & Diseases},
year = {2023},
volume = {10},
number = {6},
pages = {2278--2281},
doi = {10.1016/j.gendis.2023.01.021}
}
EUVIMED